ArriVent BioPharma, Inc. (AVBP) — Financial statements
Income statement, balance sheet, and cash flow for ArriVent BioPharma, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 153↑94.1% | 79↑21.8% | 65↑113.2% | 30↑373.0% | 6 | |
| General & Administrative Expenses | 24↑58.0% | 15↑57.7% | 10↑49.9% | 6 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 24↑58.0% | 15↑57.7% | 10↑49.9% | 6↑186.2% | 2 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 178↑88.2% | 94↑26.4% | 75↑102.1% | 37↑324.4% | 9 | |
| Total Costs & Expenses | 178↑88.2% | 94↑26.4% | 75↑102.1% | 37↑324.4% | 9 | |
| Operating Results | ||||||
| Operating Income | -178↓88.2% | -94↓26.4% | -75↓102.1% | -37↓324.4% | -9 | |
| Depreciation & Amortization | 0.00 | 0.00 | 0.00↓100.0% | 37 | 0.00 | |
| EBITDA | -178↓120.6% | -80↓7.9% | -75 | 0.00↑100.0% | -52 | |
| EBIT | -178↓120.6% | -80↓7.9% | -75↓102.1% | -37↑28.5% | -52 | |
| Interest & Other Income | ||||||
| Net Interest Income | 11↓18.8% | 14↑162.9% | 5 | 0.00 | 0.00 | |
| Interest Income | 11↓18.8% | 14↑162.9% | 5 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00↑100.0% | -14 | 0.00 | 0.00↓100.0% | 43 | |
| Other Income / Expenses | 11↓18.8% | 14↑162.9% | 5 | 0.00↑100.0% | -43 | |
| Income Before Tax | -166↓106.6% | -80↓16.1% | -69↓87.9% | -37↑28.5% | -52 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -166↓106.6% | -80↓16.1% | -69↓87.9% | -37↑28.5% | -52 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -166↓106.6% | -80↓16.1% | -69↓87.9% | -37↑28.5% | -52 | |
| Bottom-Line Net Income | -166↓106.6% | -80↓16.1% | -69↓87.9% | -37↑28.5% | -52 | |
| EPS (Basic) | -4.32↓68.8% | -2.56↓18.0% | -2.17↓97.3% | -1.10↑97.3% | -40.44 | |
| EPS (Diluted) | -4.32↓68.8% | -2.56↓18.0% | -2.17↓97.3% | -1.10↑97.3% | -40.44 | |
| Weighted Average Shares | 38↑22.2% | 31↓1.5% | 32↓4.6% | 33↑2524.9% | 1 | |
| Weighted Average Diluted Shares | 38↑22.2% | 31↓1.5% | 32↓4.6% | 33↑2524.4% | 1 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.